Jun
10
2011
0

Phase 3 STRIVE Study Of VX-770 Showed Durable Improvements In Lung Function And Other Measures Of Disease Among People With A Specific Type Of CF

Originally posted in Cystic Fibrosis News From Medical News Today

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF). STRIVE was designed to evaluate VX-770 among 161 people 12 years or older with a mutation known as G551D in the CF gene…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jun
10
2011
0

Vertex Plans to Provide Access to Potential CF Therapy VX-770 for Patients with Critical Medical Need

Originally posted in Cystic Fibrosis Foundation

Written by Cystic Fibrosis Foundation in: News & Events |

Jun
10
2011
0

Vertex Plans to Provide Access to Potential CF Therapy VX-770 for Patients with Critical Medical Need

Originally posted in Cystic Fibrosis Foundation

Written by Cystic Fibrosis Foundation in: News & Events |

Jun
10
2011
0

VX-770 Shows Positive and Lasting Results Throughout 48-Week Phase 3 Study

Originally posted in Cystic Fibrosis Foundation

Written by Cystic Fibrosis Foundation in: News & Events |

Jun
10
2011
0

VX-770 Shows Positive and Lasting Results Throughout 48-Week Phase 3 Study

Originally posted in Cystic Fibrosis Foundation

Written by Cystic Fibrosis Foundation in: News & Events |

Jun
10
2011
0

Mutations In Essential Genes Often Cause Rare Diseases

Originally posted in Cystic Fibrosis News From Medical News Today

Mutations in genes essential to survival are behind so-called orphan diseases, explaining in part why these diseases are rare and often deadly, according to a study appearing in The American Journal of Human Genetics…

Written by Cystic Fibrosis News From Medical News Today in: Genetics |

Jun
10
2011
0

Phase 2 Study Of Two Potential CF Therapies – VX-770 And VX-809 – Shows Promising Results In Patients With Most Common Mutation

Originally posted in Cystic Fibrosis News From Medical News Today

Vertex Pharmaceuticals Incorporated and the Cystic Fibrosis Foundation today announced promising results from an ongoing Phase 2 study evaluating combinations of VX-770 and VX-809, potential medicines designed to treat the defective protein that causes cystic fibrosis. The study enrolled 62 people with two copies of the most common CF mutation, known as Delta F508. The trial lasted three weeks…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Bookmark Us!

©Uncle & Drunken Crayfish Productions 2011 www.DrunkenCrayfish.com DrunkenCrayfish

Visit our NEW site at PocketBiker.com
PocketBiker.com Logo

 

TheBuckmaker.com Wordpress Themes | Hosting Provider, Mixed-Tape Free Music